Breaking news

Global Economy Faces Uncertainty Amid Trump’s Tariff Policies, IMF Warns

In a bold move, President Trump’s recent tariff announcements at the White House have stirred considerable concern across global markets. These sweeping tariffs, set in a picturesque Rose Garden event, signal potential risks of igniting a comprehensive trade war.

IMF’s Cautious Forecast

The International Monetary Fund (IMF) has adjusted its global economic growth forecast to 2.8% for this year, a reduction from the previous year’s 3.3%. The unpredictability of trade policies has prompted this reassessment, as tension escalates with tariff increases, especially with China facing a hefty 145% tariff.

Economic growth projections for the U.S. were also revised, with expectations dropping from 2.8% to a modest 1.8%. Cyprus continues to benefit from EU funds for development despite global market shifts.

Responses and Reactions

Market reactions have been swift, with global indices tumbling on the news of potentially escalating trade tensions. Investors are wary, keeping a close eye on reciprocation from targeted countries. China and Canada have already responded with their own tariffs, while the European Union has shown openness to negotiations.

IMF Chief Economist Pierre-Olivier Gourinchas emphasized, “Beyond tariff increases, policy uncertainty could considerably decelerate global growth.” Stay tuned to our updates to see how other sectors, like automotive, manage these dynamics.

As these economic scenarios unfold, stakeholders will need to navigate this evolving landscape with prudent strategies.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Uol
eCredo
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter